Skip to Content

Personalized mini-tumors could predict when cancer drugs will work

February 22, 2018

Researchers used cells taken from 71 patients with colon and rectal cancer and grew miniature 3-D tumors that were specific to each person.

What they did: Scientists tested 55 different drugs—some currently available and others experimental—on all the mini-tumors (also known as “organoids”).

The findings: The technique was better at predicting whether a drug would work against a patient’s cancer than simply sequencing a tumor’s DNA. The organoids were 88 percent successful at forecasting whether a patient would respond well to a given drug and were always correct when it came to predicting that a therapy would not be effective, according to results published in the journal Science.

Why it matters: Nicola Valeri, one of the study authors and an investigator at the Institute of Cancer Research in London, says patient-derived organoids can be used to craft ideal individualized treatment plans. He says they would be particularly useful in sorting cancer patients into the right clinical trials, making it more likely that a drug would succeed.

Deep Dive


The first babies conceived with a sperm-injecting robot have been born

Meet the startups trying to engineer a desktop fertility machine.

Doctors have performed brain surgery on a fetus in one of the first operations of its kind

A baby girl who developed a life-threatening brain condition was successfully treated before she was born—and is now a healthy seven-week-old.

A brain implant changed her life. Then it was removed against her will.

Her case highlights why we need to enshrine neuro rights in law.

The FDA just approved rub-on gene therapy that helps “butterfly” children

Biotech companies are getting creative with how they deliver DNA fixes into people's bodies.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.